Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Core Insights - Nektar Therapeutics presented preclinical data on NKTR-422, a novel modified hematopoietic colony stimulating factor, at the 2024 American College of Rheumatology conference, highlighting its potential in inflammation resolution and tissue repair [1][4]. Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate being rezpegaldesleukin (NKTR-358) [5]. Product Details - NKTR-422 is engineered to selectively modulate inflammation resolution by targeting anti-inflammatory tissue resident macrophages, showing promise in preclinical models for chronic inflammatory conditions [2][3]. - The drug has a differentiated pharmacokinetic and pharmacodynamic profile compared to native CSF-1, allowing for sustained activity from a single dose, unlike traditional multiple daily doses [3]. Clinical Potential - Early data suggest that NKTR-422 may enhance treatment efficacy and improve disease remission, particularly when used in combination with standard inflammatory cytokine blockade therapies [4].